REFERENCES
- KesslerRC.PetukhovaM.SampsonNA.ZaslavskyAM.WittchenHU.Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States.Int J Methods Psychiatr Res.201221316918422865617
- WittchenHU.JacobiF.RehmJ.et alThe size and burden of mental disorders and other disorders of the brain in Europe 2010.Eur Neuropsychopharmacol.201121965567921896369
- ChisholmD.SweenyK.SheehanP.et alScaling-up treatment of depression and anxiety: a global return on investment analysis.Lancet Psychiatry.20163541542427083119
- JacobiF.HoflerM.StrehleJ.et alMental disorders in the general population: study on the health of adults in Germany and the additional module mental health (DEGS1-MH) [in German].Nervenarzt.2014851778724441882
- KesslerRC.McGonagleKA.ZhaoS.et alLifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.Arch Gen Psychiatry.19945118198279933
- KesslerRC.DemlerO.FrankRG.et alPrevalence and treatment of mental disorders, 1990 to 2003.N Engl J Med.2005352242515252315958807
- BandelowB.MichaelisS.Epidemiology of anxiety disorders in the 21st century.Dialogues Clin Neurosci.201517332733526487813
- KesslerRC.BerglundP.DemlerO.JinR.MerikangasKR.WaltersEE.Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.Arch Gen Psychiatry.200562659360215939837
- AngstJ.GammaA.BaldwinDS.Ajdacic-GrossV.RosslerW.The generalized anxiety spectrum: prevalence, onset, course and outcome.Eur Arch Psychiatry Clin Neurosci.20092591374518575915
- BandelowB.Epidemiology of depression and anxiety. In: Kasper S, den Boer JA, Ad Sitsen JM, eds.Handbook on Depression and Anxiety. New York, NY: M Dekker20034968
- RubioG.Lopez-IborJJ.Generalized anxiety disorder: a 40-year follow-up study.Acta Psychiatr Scand.2007115537237917430415
- RubioG.Lopez-IborJJ Jr.What can be learnt from the natural history of anxiety disorders?Eur Psychiatry.2007222808617184975
- BandelowB.BaldwinD.AbelliM.et alBiological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: neuroimaging and genetics.World J Biol Psychiatry.201617532136527403679
- BandelowB.BaldwinD.AbelliM.et alBiological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: neurochemistry, neurophysiology and neurocognition.World J Biol Psychiatry.201718316221427419272
- WittchenHU.KesslerRC.BeesdoK.KrauseP.HoflerM.HoyerJ.Generalized anxiety and depression in primary care: prevalence, recognition, and management.J Clin Psychiatry.200263(suppl 8)2434
- MollerHJ.BandelowB.BauerM.et alDSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 1: general aspects and paradigmatic discussion of depressive disorders.Eur Arch Psychiatry Clin Neurosci.2015265151825119146
- BandelowB.Comparison of the DSM-5 and ICD-10: panic and other anxiety disorders.CNS Spectr.201713
- BaldwinDS.GordonR.AbelliM.PiniS.The separation of adult separation anxiety disorder.CNS Spectr.201621428929427503572
- World Health Organization. ICD-11 Beta Draft. World Health Organization; 2017. http://apps.who.int/classifications/icd11/browse/f/en. Accessed February 17, 2017
- MollerHJ.BandelowB.VolzHP.BarnikolUB.SeifritzE.KasperS.The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice.Eur Arch Psychiatry Clin Neurosci.2016266872573627002521
- KesslerRC.ChiuWT.DemlerO.MerikangasKR.WaltersEE.Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.Arch Gen Psychiatry.200562661762715939839
- AlonsoJ.AngermeyerMC.BernertS.et al12-Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project.Acta Psychiatr Scand Suppl.2004 420283715128385
- HamiltonM.The assessment of anxiety states by rating.Br J Med Psychol.1959321505513638508
- BandelowB.BroocksA.PekrunG.et alThe use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial.Pharmacopsychiatry.200033517418111071019
- LiebowitzMR.Social phobia.Mod Probl Pharmacopsychiatry.1987221411732885745
- BandelowB.SherL.BuneviciusR.et alGuidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.int J Psychiatry Clin Pract.2012162778422540422
- BandelowB.LichteT.RudolfS.WiltinkJ.BeutelME.The German guidelines for the treatment of anxiety disorders.Eur Arch Psychiatry Clin Neurosci.2015265536337325404200
- BaldwinDS.AndersonIM.NuttDJ.et alEvidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.J Psychopharmacol.201428540343924713617
- RegierDA.NarrowWE.RaeDS.ManderscheidRW.LockeBZ.GoodwinFK.The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services.Arch Gen Psychiatry.199350285948427558
- AlonsoJ.LepineJP.ESEMeD/MHEDEA 2000 Scientific Committee. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD).J Clin Psychiatry.200768suppl 239
- SmoldersM.LaurantM.VerhaakP.et alAdherence to evidence-based guidelines for depression and anxiety disorders is associated with recording of the diagnosis.Gen Hosp Psychiatry.200931546046919703640
- BenjaminJ.Ben-ZionIZ.KarbofskyE.DannonP.Double-blind placebo-controlled pilot study of paroxetine for specific phobia.Psychopharmacology (Berl).2000149219419610805616
- BandelowB.ZoharJ.HollanderE.et alWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders -first revision.World J Biol Psychiatry.20089424831218949648
- CiprianiA.FurukawaTA.SalantiG.et alComparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.Lancet.2009373966574675819185342
- MuscatelloMR.SpinaE.BandelowB.BaldwinDS.Clinically relevant drug interactions in anxiety disorders.Hum Psychopharmacol.201227323925322311403
- StahlMM.LindquistM.PetterssonM.et alWithdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system.Eur J Clin Pharmacol.1997533-41631699476026
- BaldwinDS.AjelK.MasdrakisVG.NowakM.RafiqR.Pregabalin for the treatment of generalized anxiety disorder: an update.Neuropsychiatr Dis Treat.2013988389223836974
- ThanacoodyHK.ThomasSH.Tricyclic antidepressant poisoning: cardiovascular toxicity.Toxicol Rev.200524320521416390222
- StahlSM.Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder.J Clin Psychiatry.200263975675712363113
- StarcevicV.The reappraisal of benzodiazepines in the treatment of anxiety and related disorders.Expert Rev Neurother.201414111275128625242262
- SchweizerE.RickelsK.CaseWG.GreenblattDJ.Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper.Arch Gen Psychiatry.199047109089152222130
- RickelsK.SchweizerE.CaseWG.GreenblattDJ.Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation [published erratum appears in Arch Gen Psychiatry 1991;48(1):51].Arch Gen Psychiatry.199047108999072222129
- SmithDE.LandryMJ.Benzodiazepine dependency discontinuation: focus on the chemical dependency detoxification setting and benzodiazepine-polydrug abuse.J Psychiatr Res.199024suppl 21451561980693
- BradwejnJ.Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions.Can J Psychiatry.199338suppl 4S109S1137905780
- ShaderRI.GreenblattDJ.Use of benzodiazepines in anxiety disorders.N Engl J Med.1993328139814058292115
- LivingstonMG.Benzodiazepine dependence.Br J Hosp Med.19945162812868032563
- NelsonJ.ChouinardG.Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology.Can J Clin Pharmacol.199962698310519733
- SchweizerE.RickelsK.De MartinisN.CaseG.Garcia-EspanaF.The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients.Psychol Med.19982837137209626727
- RickelsK.Benzodiazepines in the treatment of anxiety.Am J Psychother.19823633583706128929
- BandelowB.LichteT.RudolfS.WiltinkJ.BeutelME.The diagnosis of and treatment recommendations for anxiety disorders.Dtsch Arztebl Int.201411127-2847348025138725
- BerneyP.HalperinD.TangoR.Daeniker-DayerI.SchulzP.A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders.Psychopharmacol Bull.2008413394718779775
- GoddardAW.BrouetteT.AlmaiA.JettyP.WoodsSW.CharneyD.Early coadministration of clonazepam with sertraline for panic disorder.Arch Gen Psychiatry.200158768168611448376
- OttoMW.PollackMH.SachsGS.ReiterSR.Meltzer-BrodyS.RosenbaumJF.Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder.Am J Psychiatry.199315010148514908379551
- SpiegelDA.Psychological strategies for discontinuing benzodiazepine treatment.J Clin Psychopharmacol.1999196 suppl 217S22S10587280
- SteinDJ.AhokasAA.de BodinatC.Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.J Clin Psychopharmacol.200828556156618794654
- SteinDJ.AhokasA.AlbarranC.OlivierV.AllgulanderC.Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.J Clin Psychiatry.20127371002100822901350
- SteinDJ.AhokasA.MarquezMS.et alAgomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.J Clin Psychiatry.201475436236824569045
- SteinDJ.AhokasA.JaremaM.et alEfficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.Eur Neuropsychopharmacol.20172752653728298261
- MontgomerySA.KennedySH.BurrowsGD.LejoyeuxM.HindmarchI.Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, doubleblind, placebo-controlled discontinuation study.Int Clin Psychopharmacol.200419527128015289700
- GoodwinGM.EmsleyR.RembryS.RouillonF.Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.J Clin Psychiatry.20097081128113719689920
- SerrettiA.ChiesaA.Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.J Clin Psychopharmacol.200929325926619440080
- McAllister-WilliamsRH.BaldwinDS.HaddadPM.BazireS.The use of antidepressants in clinical practice: focus on agomelatine.Hum Psychopharmacol.20102529510220196187
- BandelowB.ChouinardG.BobesJ.et alExtended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placeboand active-controlled study.Int J Neuropsychopharmacol.201013330532019691907
- KhanA.JoyceM.AtkinsonS.EggensI.BaldytchevaI.ErikssonH.A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.J Clin Psychopharmacol.201131441842821694613
- FuJ.PengL.LiX.The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis.Neuropsychiatr Dis Treat.20161295195927143896
- KasperS.GastparM.MullerWE.et alLavender oil preparation Silexan is effective in generalized anxiety disorder -a randomized, double+-blind comparison to placebo and paroxetine.Int J Neuropsychopharmacol.201417685986924456909
- KasperS.AnghelescuI.DienelA.Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep - a randomized, placebo-controlled trial.Eur Neuropsychopharmacol.201525111960196726293583
- KasperS.VolzHP.DienelA.SchlafkeS.Efficacy of Silexan in mixed anxiety-depression -a randomized, placebo-controlled trial.Eur Neuropsychopharmacol.201626233134026718792
- WoelkH.SchlafkeS.A multi-center, double-blind, randomised study of the lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorder.Phytomedicine.2010172949919962288
- JacobsBP.BentS.TiceJA.BlackwellT.CummingsSR.An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia.Medicine (Baltimore).200584419720716010204
- ConnorKM.PayneV.DavidsonJR.Kava in generalized anxiety disorder: three placebo-controlled trials,int Clin Psychopharmacol.200621524925316877894
- SarrisJ.StoughC.BousmanCA.et alKava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study.J Clin Psychopharmacol.201333564364823635869
- AndreatiniR.SartoriVA.SeabraML.LeiteJR.Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebocontrolled pilot study.Phytother Res.200216765065412410546
- KobakKA.TaylorLV.BystritskyA.et alSt John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study.Int Clin Psychopharmacol.200520629930416192837
- SarrisJ.PanossianA.SchweitzerI.StoughC.ScholeyA.Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence.Eur Neuropsychopharmacol.2011211284186021601431
- WurglicsM.WesterhoffK.KaunzingerA.et alComparison of German St. John's wort products according to hyperforin and total hypericin content.J Am Pharm Assoc (Wash).200141456056611486982
- BandelowB.ReittM.RoverC.MichaelisS.GorlichY.WedekindD.Efficacy of treatments for anxiety disorders: a meta-analysis.Int Clin Psychopharmacol.201530418319225932596
- DurhamRC.ChambersJA.PowerKG.et alLong-term outcome of cognitive behaviour therapy clinical trials in central Scotland.Health Technol Assess.20059421174
- StocchiF.NorderaG.JokinenRH.et alEfficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder.J Clin Psychiatry.200364325025812716265
- MontgomerySA.NilR.Durr-PalN.LoftH.BoulengerJP.A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.J Clin Psychiatry.200566101270127816259540
- SteinDJ.VersianiM.HairT.KumarR.Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study.Arch Gen Psychiatry.200259121111111812470127
- DavidsonJR.WittchenHU.LlorcaPM.et alDuloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.Eur Neuropsychopharmacol.200818967368118559291
- KatzmanMA.Brawman-MintzerO.ReyesEB.OlaussonB.LiuS.ErikssonH.Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.Int Clin Psychopharmacol.2011261112420881846
- BaldwinDS.SteinDJ.DolbergOT.BandelowB.How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.Hum Psychopharmacol.200924426927519334042
- YoshinagaN.MatsukiS.NiitsuT.et alCognitive behavioral therapy for patients with social anxiety disorder who remain symptomatic following antidepressant treatment: a randomized, assessor-blinded, controlled trial.Psychother Psychosom.201685420821727230862
- SchuurmansJ.van BalkomA.Late-life anxiety disorders: a review.Curr Psychiatry Rep.201113426727321538031
- HallJ.KellettS.BerriosR.BainsMK.ScottS.Efficacy of cognitive behavioral therapy for generalized anxiety disorder in older adults: systematic review, meta-analysis, and meta-regression.Am J Geriatr Psychiatry.201624111063107327687212
- HussainFS.DobsonET.StrawnJR.Pharmacologic treatment of pediatric anxiety disorders.Curr Treat Options Psychiatry.20163215116027648401
- IpserJC.SteinDJ.HawkridgeS.HoppeL.Pharmacotherapy for anxiety disorders in children and adolescents.Cochrane Database Syst Rev.2009 3CD00517019588367
- WalkupJT.AlbanoAM.PiacentiniJ.et alCognitive behavioral therapy, sertraline, or a combination in childhood anxiety.N Engl J Med.2008359262753276618974308
- Committee on Safety of Medicines (2014). Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs): use and safety. Medicines & Healthcare products Regulatory Agency (MHRA). Available at: https://www.gov.uk/government/publications/ssris-and-snris-use-and-safety/selective-serotonin-reuptake-inhibitors-ssris-and-serotonin-and-noradrenaline-reuptake-inhibitors-snris-useand-safety. Accessed 18 May 2017.
- HetrickSE.McKenzieJE.CoxGR.SimmonsMB.MerrySN.Newer generation antidepressants for depressive disorders in children and adolescents.Cochrane Database Syst Rev.201211CD00485123152227
- LibbyAM.BrentDA.MorratoEH.OrtonHD.AllenR.ValuckRJ.Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.Am J Psychiatry.2007164688489117541047
- GibbonsRD.BrownCH.HurK.et alEarly evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.Am J Psychiatry.200716491356136317728420
- MohattJ.BennettSM.WalkupJT.Treatment of separation, generalized, and social anxiety disorders in youths.Am J Psychiatry2014171774174824874020
- BergmanRL.GonzalezA.PiacentiniJ.KellerML.Integrated Behavior Therapy for Selective Mutism: a randomized controlled pilot study.Behav Res Ther.2013511068068923933108
- OerbeckB.SteinMB.Wentzel-LarsenT.LangsrudO.KristensenH.A randomized controlled trial of a home and school-based intervention for selective mutism - defocused communication and behavioural techniques.Child Adolesc Ment Health.2014193192198
- ManassisK.OerbeckB.OvergaardKR.The use of medication in selective mutism: a systematic review.Eur Child Adolesc Psychiatry.201625657157826560144
- HuybrechtsKF.PalmstenK.AvornJ.et alAntidepressant use in pregnancy and the risk of cardiac defects.N Engl J Med.2014370252397240724941178
- OyebodeF.RastogiA.BerrisfordG.CocciaF.Psychotropics in pregnancy: safety and other considerations.Pharmacol Ther.20121351717722483705
- MuzikM.HamiltonSE.Use of antidepressants during pregnancy?: What to consider when weighing treatment with antidepressants against untreated depression.Matern Child Health J.201620112268227927461022
- GilroyLJ.KirkbyKC.DanielsBA.MenziesRG.MontgomeryIM.Controlled comparison of computer-aided vicarious exposure versus live exposure in the treatment of spider phobia.Behavior Therapy.2001314733744
- PattersonB.BoyleMH.KivlenieksM.Van AmerlngenM.The use of waitlists as control conditions in anxiety disorders research.J Psychiatr Res.20168311212027585425
- JamesAC.JamesG.CowdreyFA.SolerA.ChokeA.Cognitive behavioural therapy for anxiety disorders in children and adolescents.Cochrane Database Syst Rev.2015 2CD00469025692403
- BroocksA.BandelowB.PekrunG.et alComparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder.Am J Psychiatry.199815556036099585709
- WedekindD.BroocksA.WeissN.EngelK.NeubertK.BandelowB.A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder.World J Biol Psychiatry.201011790491320602575
- World Health Organization.ICD-10 Chapter V (F) Classification of Mental and Behvioural Disorders: Clinical Descriptions and Diagnostic Guidelines. “Blue Book” Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization;1991